10x Genomics (TXG) is a provider of the next generation of biological instruments that are described as being part par of the "single-cell revolution" They are scheduled to price their IPO this Wednesday night and have raised their pricing range to $36-38. Investors are excited about the opportunity despite an overhang of litigation in the space. (We've seen similar litigation patterns when the CRISPR companies came public - EDIT, NTLA, CRSP.) Everyone wants to get on the next Illumina (ILMN.)
A common thread in a number of new biotechnology tools and approaches has . . .